[1] 中华医学会肝病学分会、消化病学分会、感染病学分会.胆汁淤积性肝病诊断和治疗共识(2015).实用肝脏病杂志,2016,19(6):Ⅰ-ⅩⅠ.
[2] Chung SW, Lee JH, Kim MA. Additional fibrate treatment in UDCA-refractory PBC patients. Liver Int, 2019, 39(9): 1776-1785.
[3] Erlinger S. Obeticholic acid in primary biliary cholangitis. Clin Res Hepatol Gastroenterol, 2017, 41(1): 3-5.
[4] Joyce SA, Gahhan CG. Disease-associated changes in bile acid profiles and links to altered gut microbiota. Dig Dis, 2017, 35(3):169-177.
[5] Lindor KD,Bowlus CL,Boyer J,et al. Primary biliary cholangitis: 2018 practice guidance from the American asociation for the study of liver diseases. Hepatology, 2019,69(1):394-419.
[6] Hirschfield GM,Beuers U,Corpechot C,et al. EASL clinical practice guidelines:the diagnosis and management of patients with primary biliary cholangitis.J Hepatol,2017,67(1): 145-172.
[7] Lazaridis KN, Gores GJ, Lindor KD. 2001. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders.' J Hepatol, 2015,35:134-146.
[8] Beuers H. Druginsight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.Nat Clin Pract Gastroenterol Hepatol,2006, 3:318-328.
[9] Arab JP, Cabrera D, Arrese M. Bile acids in cholestasis and its treatment.Ann Hepatol, 2017,16(Suppl 1):53-57.
[10] Fickert P, Hirschfield GM, Denk G, et al. non-Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol, 2017,67:549-558.
[11] Pellicciari R, Fiorucci S,Camaioni E, et al. 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem, 2002, 45:3569-3572.
[12] Ali AH, Lindor KD. Obeticholic acid for the treatment of primary biliary cholangitis .Expert Opin Pharmacother, 2016, 17(13): 1809-1815.
[13] Bowlus CL, Pockros PJ,Kremer AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis .Clin Gastroenterol Hepatol,2020,18(5): 1170-1178.
[14] Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and in adequate response to ursodeoxycholic acid. Gastroenterology,2015,148:751-761.
[15] Michael T, Aliya G, Bilal H, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis . Hepatology,2019, 70 (3): 788-801.
[16] Carey EJ,Ali AH,Lindor KD. Primary biliary cirhosis. Lancet,2015,386(10003):1565-1575.
[17] Mayo MJ, Wigg AJ, Roberts SK, et al. NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial. Hepatology (Baltimore, MD), 2015,62: 263-264.
[18] Dubois V,Eeckhoute J,Lefebvre P, al al. Distinct Buomplementary contributions of PPAR isotypes to energy homeostasis. J Clin, Investig,2017,127:1202-1214.
[19] Corpechot C, Chazouilleres O, Rousseau A, et al. A placebo- controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med, 2018,378:2171-2181.
[20] Corpechot C, Chazouilleres O, Rousseau A, et al. A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso). J Hepatol,2017,66:S89.
[21] Jones D, Boudes PF, Swain MG, et al. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol, 2017, 2:716-726.
[22] Hgade VS, Kendrick SF, Dobbins RL, et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet, 2017, 389(10074): 1114-1123.
[23] Al-Dury S, Wahlstrom A, Wahlin S, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.Sci Rep,2018, 8(1): 6658.
[24] Hirschfield GM, Gershwin ME,Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology,2017, 64:189-99.
[25] Bowlus CL,Yang GX,Liu CH, et al. Therapeutic trials of biologics in primary biliary cholangitis: an open label study of abatacept and review of the literature. J Autoimmun,2019, 101:26-34.
[26] Wagner M, Fickert P. Drug therapies for chronic cholestatic liver diseases. Annu Rev Pharmacol Toxicol, 2020,60:503-527.
[27] Muir A, Goodman Z, Levy C, et al. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial. J Hepatol,2017,66:S73.
[28] Zhou J, Huang N, Guo Y, et al. Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis. Acta Pharm Sin B, 2019,9(3):526-536. |
